Evolving Strategies for Leveraging SGLT2 Inhibitor Therapy in Type 2 Diabetes

SGLT2 inhibitors play important roles in our new person-centric approach for managing T2D. Here’s my take on how SGLT2 inhibitors can be used to mitigate cardiovascular and renal disease, along with how I approach treatment selection in challenging clinical scenarios.

Martin J. Abrahamson, MD, FACP Physicians: maximum of 0.25 AMA PRA Category 1 Credits™ Registered Nurses: 0.25 Nursing contact hours Released: November 10, 2020 Expired: November 9, 2021